Madison, WI, United States
Madison, WI, United States

Time filter

Source Type

MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial results for first quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 4:30 PM ET today. Summary of Q1 and Q2 2017 Accomplishments to Date: “We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.” Research and development expenses were $1.9 million, an increase of $0.8 million from the same period the prior year, largely a result of the increase in activities surrounding the initiation of the company’s Phase 2 clinical trial of CLR 131 in hematologic malignancies in addition to the ongoing Phase 1 trial in relapse/refractory multiple myeloma.  General and administrative expenses totaled $1.0 million, consistent with Q1 2016. The operating loss was $2.8 million, compared to $2.0 million in 2016.  Net loss for the first quarter of 2017 was $2.9 million, or $0.24 per share, compared to net income of $0.8 million, or $0.96 per share, for the first quarter of 2016. As of March 31, 2017, Cellectar reported $11.2 million in cash and cash equivalents on hand, compared to $11.4 million in cash and cash equivalents as of December 31, 2016. Finally, the company received approximately $3 million from warrants exercised during the quarter, which extends Cellectar’s available cash and cash equivalents to fund planned operations into the second quarter of 2018.  This is an improvement from the previous guidance of funding into the first quarter 2018.  Additional capital will be required for operations beyond the second quarter of 2018. Conference Call Details Cellectar will be holding a conference call at 4:30 PM ET today to review Q1 2017 financial results, and corporate performance. The call may be accessed by dialing (888) 646-8293 (US domestic) or (973) 453-3065 (international), or participate via webcast at http://edge.media-server.com/m/p/2qdweuf4. The live and archived webcast can also be accessed via the company’s website at http://investor.cellectar.com/events.cfm. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com. This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016.  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial results for first quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 4:30 PM ET today. Summary of Q1 and Q2 2017 Accomplishments to Date: “We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.” Research and development expenses were $1.9 million, an increase of $0.8 million from the same period the prior year, largely a result of the increase in activities surrounding the initiation of the company’s Phase 2 clinical trial of CLR 131 in hematologic malignancies in addition to the ongoing Phase 1 trial in relapse/refractory multiple myeloma.  General and administrative expenses totaled $1.0 million, consistent with Q1 2016. The operating loss was $2.8 million, compared to $2.0 million in 2016.  Net loss for the first quarter of 2017 was $2.9 million, or $0.24 per share, compared to net income of $0.8 million, or $0.96 per share, for the first quarter of 2016. As of March 31, 2017, Cellectar reported $11.2 million in cash and cash equivalents on hand, compared to $11.4 million in cash and cash equivalents as of December 31, 2016. Finally, the company received approximately $3 million from warrants exercised during the quarter, which extends Cellectar’s available cash and cash equivalents to fund planned operations into the second quarter of 2018.  This is an improvement from the previous guidance of funding into the first quarter 2018.  Additional capital will be required for operations beyond the second quarter of 2018. Conference Call Details Cellectar will be holding a conference call at 4:30 PM ET today to review Q1 2017 financial results, and corporate performance. The call may be accessed by dialing (888) 646-8293 (US domestic) or (973) 453-3065 (international), or participate via webcast at http://edge.media-server.com/m/p/2qdweuf4. The live and archived webcast can also be accessed via the company’s website at http://investor.cellectar.com/events.cfm. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com. This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016.  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


On Monday, shares in San Rafael, California headquartered BioMarin Pharmaceutical Inc. saw a drop of 3.72%, ending the day at $90.72. The stock recorded a trading volume of 1.91 million shares, which was above its three months average volume of 1.14 million shares. The Company's shares have advanced 4.41% in the last one month, 2.23% over the previous three months, and 9.51% since the start of this year. The stock is trading above its 200-day moving average by 0.72%. Moreover, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have a Relative Strength Index (RSI) of 44.79. On May 04th, 2017, BioMarin Pharma announced financial results for Q1 ended March 31st, 2017. GAAP net loss was $16 million, non-GAAP income was $35 million, and total revenues were $304 million. In addition, the Company had cash, cash equivalents and investments totaling $1.2 billion as of March 31st, 2017, compared to $1.4 billion on December 31st, 2016. BMRN complete research report is just a click away and free at: Shares in Waltham, Massachusetts headquartered Eyegate Pharmaceuticals Inc. ended the day 7.94% lower at $1.89 with a total trading volume of 168,835 shares. In the previous three months and on an YTD basis, the stock has gained 24.34% and 15.95%, respectively. The Company's shares are trading above their 200-day moving average by 0.31%. Furthermore, shares of Eyegate Pharma, which focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye, have an RSI of 36.87. On May 04th, 2017, Eyegate Pharma announced that the Company has submitted an Investigational Device Exemption (IDE) for the lead product in its cross-linked thiolated carboxymethyl hyaluronic acid platform, EyeGate Ocular Bandage Gel (EyeGate OBG). The IDE, if accepted, will enable the Company to initiate a second pilot study of EyeGate OBG for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy. The complimentary report on EYEG can be downloaded at: At the close of trading on Monday, shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc. finished 1.74% higher at $0.55 with a total trading volume of 293,087 shares. The stock has advanced 9.88% in the last one month and 5.65% over the previous three months. The Company's shares are trading below their 50-day moving average by 0.36%. Additionally, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 57.02. On April 25th, 2017, Navidea Biopharmaceuticals announced that it has been invited to present data at two major upcoming conferences. The Company will present at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging from June 10th to 14th, 2017 at the Colorado Convention Center in Denver. The Company will also present at the 2017 BIO International Convention from June 19th to 22nd, 2017 at the San Diego Convention Center in San Diego. Sign up for your complimentary research report on NAVB at: Madison, Wisconsin headquartered Cellectar Biosciences Inc.'s shares recorded a trading volume of 100,585 shares at the end of yesterday's session. The stock closed the day 1.05% lower at $1.88. The Company's shares have advanced 15.34% in the previous three months and 54.10% on an YTD basis. The stock is trading below its 200-day moving average by 10.37%. Additionally, shares of Cellectar Biosciences, which engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer, have an RSI of 37.58. On May 02nd, 2017, Cellectar Biosciences announced that management will host a teleconference and live webcast to report Q1 2017 financial results, followed by a review of corporate performance on May 11th, 2017 at 4:30 p.m. ET. The live and archived webcast of the call can be accessed via the Company's website. Get free access to your research report on CLRB at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial results for first quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a review of corporate performance, at 4:30 PM ET today. Summary of Q1 and Q2 2017 Accomplishments to Date: “We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.” Research and development expenses were $1.9 million, an increase of $0.8 million from the same period the prior year, largely a result of the increase in activities surrounding the initiation of the company’s Phase 2 clinical trial of CLR 131 in hematologic malignancies in addition to the ongoing Phase 1 trial in relapse/refractory multiple myeloma.  General and administrative expenses totaled $1.0 million, consistent with Q1 2016. The operating loss was $2.8 million, compared to $2.0 million in 2016.  Net loss for the first quarter of 2017 was $2.9 million, or $0.24 per share, compared to net income of $0.8 million, or $0.96 per share, for the first quarter of 2016. As of March 31, 2017, Cellectar reported $11.2 million in cash and cash equivalents on hand, compared to $11.4 million in cash and cash equivalents as of December 31, 2016. Finally, the company received approximately $3 million from warrants exercised during the quarter, which extends Cellectar’s available cash and cash equivalents to fund planned operations into the second quarter of 2018.  This is an improvement from the previous guidance of funding into the first quarter 2018.  Additional capital will be required for operations beyond the second quarter of 2018. Conference Call Details Cellectar will be holding a conference call at 4:30 PM ET today to review Q1 2017 financial results, and corporate performance. The call may be accessed by dialing (888) 646-8293 (US domestic) or (973) 453-3065 (international), or participate via webcast at http://edge.media-server.com/m/p/2qdweuf4. The live and archived webcast can also be accessed via the company’s website at http://investor.cellectar.com/events.cfm. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase I clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase II clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com. This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016.  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


MADISON, Wis., May 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces preclinical data from three abstracts demonstrating the utility of the company’s lead compound, CLR 131, for use in a variety of tumor types in single-dose and multi-dose regimens. The abstracts were published as part of the 2017 ASCO Annual Meeting Proceedings. “These peer-reviewed studies, while early stage, further demonstrate the variety of potential applications and dosing regimens for CLR 131.  In these preclinical models, we have observed measurable reduction compared to a control in tumor growth of three different cancer types while also showing a clear survival benefit,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “While CLR 131 is currently in Phase 1 and Phase 2 trials for blood cancers, the publication of these abstracts indicate promise in solid tumors, and provide further data on the potential benefit of a multi-dose regimen.” In the first study, 20 mice were injected with glioma (brain) tumor cells (U87-MG).  Investigators then injected two doses of CLR 131 (95.7µCi and 109.0 µCi on day 0 and day 7, respectively) or a control group of I-127-CLR 1404 (N=8 per group). The expected 25-fold increase in tumor burden observed in the control arm over the four-week study was reduced by 50 percent in the CLR 131 arm with additional survival benefit. In fact, the two doses of CLR 131 provided a 50 percent increase in survival over a single dose of CLR 131 in the same model. The second study involved female mice receiving two doses of CLR 131 (approximately 130 µCi and approximately 145 µCi at days 0 and 20, respectively) as well as a control group of I-127-CLR 1404 (N=8 per group), following injection of female mice with a MES SA/Dx5 cell line (human uterine sarcoma).  This model was selected because of its high level of expression of resistance mechanisms these tumor cells exhibit, specifically P-gp efflux pumps that eject many chemotherapeutics from the cell.  The active treatment group (CLR 131) experienced a 66 percent reduction of the expected 21-fold increase in tumor burden observed in the control group.  This resulted in nearly doubling the survival time for the mice receiving two doses of CLR 131. The final study entailed the injection of mice with Caki-2 cell line (human clear cell carcinoma, common in renal cancer).  Once tumor size reached a pre-determined volume, these mice received either a single dose of CLR 131 (approximately 110µCi), or a control of I-127-CLR 1404 (N=8 per group).  The control group showed exponential growth at 20 days post-injection, while the treatment group experienced a reduction in the initial tumor volume through day 65 post-injection and had the same initial tumor volume at day 75 post-injection.  By day 65, the control group increased 10.75-fold compared to the treatment group in average tumor volume. About CLR 131 CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated as a single-dose treatment in a Phase 1 clinical trial in patients with relapsed or refractory (R/R) multiple myeloma (MM) as well as in a Phase 2 clinical trial for R/R MM and select R/R lymphomas with either a one- or two-dose treatment. Based upon preclinical and interim Phase 1 study data, treatment with CLR 131 provides a novel approach to treating hematological diseases and may provide patients with therapeutic benefits, including overall survival, an improvement in progression-free survival, surrogate efficacy marker response rate, and overall quality of life. CLR 131 utilizes the company's patented PDC tumor targeting delivery platform to deliver a cytotoxic radioisotope, iodine-131, directly to tumor cells. The FDA has granted Cellectar an orphan drug designation for CLR 131 in the treatment of multiple myeloma. About Phospholipid Drug Conjugates (PDCs) Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates (PDCs).  The company deliberately designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate both therapeutic and diagnostic applications.  The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells.  Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs have been tested in more than 80 different xenograft models of cancer. About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers.  Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging.  The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 is currently being evaluated under an orphan drug designated Phase 1 clinical study in patients with relapsed or refractory multiple myeloma.  In addition, the company has initiated a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com. This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.


News Article | May 16, 2017
Site: www.prnewswire.com

"I am going to say something that no one else has ever said in a press release. Behold!!! The ultimate pog!!!" stated Chris Lahiji. A list is down below. For more details, please visit http://www.ldmicro.com If you are a company that wishes to attend, please contact David Scher at david@ldmicro.com If you are a private or institutional investor interested in learning more about the conference, please contact Chris Lahiji at Chris@ldmicro.com Please send all modeling requests to Eric Lahiji at Eric@ldmicro.com 22nd Century (XXII) A-Mark (AMRK) Adomani Electric (private) Aethlon Medical (AEMD) Airborne Wireless (ABWN) Alimera Sciences (ALIM) Ammo Inc (POWW) Ampliphi Biosciences (APHB) Apollo Medical Holdings (AMEH) Applied DNA Science (APDN) Arch Therapeutics (ARTH) Assure Neuromonitoring (private) Asterias Bio (AST) ATA (ATAI) Atlas Technology (ATLT) Atomera (ATOM) Atossa Genetics (ATOS) AudioEye (AEYE) Auxilio (AUXO) Aytu Bioscience (AYTU) Barfresh Food Group (BRFH) BioHighTech (BHTG) Biomerica (BMRA) BioRestorative Therapies (BRTX) BioTime (BTX) BioVie (BIVI) BlackRidge Technology (private) BrainChip Holdings (private) Caladrius Bio (CLBS) Cancer Genetics (CGIX) CASMED (CASM) Cellectar Biosciences (CLRB) Cemtrex (CETX) Chimp Change (CCA.asx) Citius Pharma (CTXR) Combimatrix (CBMX) ConversionPoint Technologies (private) CopSync (COYN) CV Sciences (CVSI) CytoDyne (CYDY) Dario Health (DRIO) Delcath (DCTH) Differential Brands (DFBG) Diffusion Pharma (DFFN) Digiliti (DGLT) Digital Power Corporation (DPW) Distinct Infrastructure Group (DUG.v) Endexx (EDXC) ENDRA Life Sciences (IPO) Ener-Core (ENCR) Enservco (ENSV) EnSync (ESNC) Exactus (EXDI) eXp World (EXPI) Finjan (FNJN) First Choice Healthcare (FCHS) Fisson (FSSN) FitLife (FTLF) Foresight (private) FORM Holdings (FH) FreeCast (private) Full House Resorts (FLL) FunctionX (FNCX) Garmatex (GRMX) Gemphire Therapeutics (GEMP) Genius Brands (GNUS) Glimpse Group (private) Grande West (BUS.v) Growgen (GRWG) Healthier Choices Management (HCMC) Helix TCS (HLIX) Her Imports (HHER) Houston American Energy (HUSA) iCAD (ICAD) Iconic Brands (ICNB) iConsumer (private) IEH Corp. (IEHC) IGEN Networks (IGEN) Inpixon (INPX) Intec Pharma (NTEC) inTest (INTT) Intevac (IVAC) Inuvo (INUV) Ironclad Encryption (IRNC) Ironclad Performance Wear (ICPW) Issuer Direct (ISDR) ITUS Corp (ITUS) Jerrick Media (JMDA) Kindred Bio (KIN) Kraken (PNG.v) Lantronix (LTRX) Legacy Education Alliance (LEAI) Lifeloc Technologies (LCTC) Lilis Energy (LLEX) LM Funding (LMFA) LottoGopher (private) Manhattan Bridge Capital (LOAN) MariMed Advisors (MRMD) Marina Biotech (MRNA) Marrone Bio (MBII) Massroots (MSRT) MaxPoint Interactive (MXPT) Medovex (MDVX) MEMEX (OEE.v) Memomi Labs (private) Meridian Waste Solutions (MRDN) Misonix (MSON) Moleculin (MBRX) Monaker (MKGI) MRI Interventions (MRIC) MRV Communications (MRVC) MusclePharm (MSLP) MyND Analytics (MYAN) NanoDimension (NNDM) NAPCO (NSSC) Navidea Biopharma (NAVB) NeuroMetrix (NURO) Nobilis Health (HLTH) NovaBay Pharma (NBY) Nuran Wireless (NRRWF) Omni-Lite (OML.v) OncoSec Medical (ONCS) OptimizeRx (OPRX) Origin Agritech (SEED) Pacific Edge Diagnostics (PEB) ParkerVision (PRKR) Pediapharm (PVP.v) Pioneering Technology Corp (PTE.v) Polar Power (POLA) Precision Aerospace (PAOS) ProFire Energy (PFIE) PwrCor (PWCO) Qyou Media (QYOU) Reign Sapphire (RGNP) Remark Media (MARK) root9B Holdings (RTNB) Rowl (private) S&W Seed (SANW) Salem Communications (SALM) Senestech (SNES) Sensus Healthcare (SRTS) Sigma Labs (SGLB) Signal Bay (SGBY) Silversun Tech (SSNT) Simulations Plus (SLP) Siyata Mobile (SIM.v) Social Reality (SRAX) Sonoma Pharmaceuticals (SNOA) Sphere 3D (ANY) Stony Hill (STNY) Style Salute (private) Sunshine Heart (SSH) Table Trac (TBTC) Tandy Leather (TLF) Teraphysics (private) The Joint Corp. (JYNT) Toughbuilt (private) TrackX (TKX.v) TrovaGene (TROV) US Nuclear (UCLE) Veru Healthcare (FHCO) Viking Therapeutics (VKTX) VistaGen (VTGN) Vitality Biopharma (VBIO) VolitionRX (VNRX) WANdisco (WAND) Xebec Adsorption (XBC.v) LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ld-micro-invitational-three-weeks-away-300458742.html

Loading Cellectar Inc. collaborators
Loading Cellectar Inc. collaborators